Clinical Trial Update: LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris [Phase 2]

View source ↗

Summary

Phase 2 trial of LEO 32731 for moderate to severe psoriasis vulgaris has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• LEO 32731

Snippet

Sponsor: LEO Pharma | Conditions: Psoriasis Vulgaris | Phase 2 | Status: COMPLETED